Statistisches Bundesamt. Genesis Online-Datenbank, Table 23631–0001: Krankheitskosten. Deutschland: Jahre, Krankheitsdiagnosen (ICD-10); 2015. (Accessed 23 Oct 2018).
Google Scholar
Heuschmann P, Busse O, Wagner M, Endres M, Villringer A, Röther J, et al. Schlaganfallhäufigkeit und Versorgung von Schlaganfallpatienten in Deutschland. Akt Neurol. 2010;37:333–40.
Article
Google Scholar
Kolominsky-Rabas PL, Heuschmann PU, Marschall D, Emmert M, Baltzer N, Neundörfer B, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke. 2006;37:1179–83.
Article
PubMed
Google Scholar
Busch MA, Schienkiewitz A, Nowossadeck E, Gößwald A. Prävalenz des Schlaganfalls bei Erwachsenen im Alter von 40 bis 79 Jahren in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56:656–60.
Article
CAS
PubMed
Google Scholar
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol. 2006;48:854–906.
Article
PubMed
Google Scholar
Perings C, Hennersdorf M, Vester EG, Weirich J, Strauer BE. Pathophysiologie, Epidemiologie und Komplikationen des Vorhofflimmerns. Der Internist. 1998;39:2–11.
Article
CAS
PubMed
Google Scholar
Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 11Reprints are not available. Am J Cardiol. 1998;82:2N–9N.
Article
CAS
PubMed
Google Scholar
Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–52.
Article
CAS
PubMed
Google Scholar
Thrall G, Lane D, Carroll D, Lip GYH. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119:448.e1–19.
Article
Google Scholar
Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920–5.
Article
PubMed
Google Scholar
Benkert D, Theres H, Wasem J, Aidelsburger P. Direkte Kosten in der Diagnostik und Behandlung von Patienten mit symptomatischem Vorhofflimmern in Deutschland. Pharmacoeconomics Ger Res Articles. 2009;7:15–27.
Article
Google Scholar
Reinhold T, Rosenfeld S, Müller-Riemenschneider F, Willich SN, Meinertz T, Kirchhof P, et al. Patienten mit Vorhofflimmern in Deutschland. Charakteristika, Ressourcenverbrauch und Kosten. Herz. 2012;37:534–42.
Article
CAS
PubMed
Google Scholar
Bramlage K, Thoenes M, Tebbe U, Bramlage P, Wasem J. Vorhofflimmern in Deutschland - Epidemiologie, Diagnostik, Therapie und Kosten. Med Monatschr Pharm. 2013;36:215–24.
Google Scholar
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–5.
Article
CAS
PubMed
Google Scholar
Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation. 2015;131:2176–84.
Article
PubMed
Google Scholar
Panisello-Tafalla A, Clua-Espuny JL, Gil-Guillen VF, González-Henares A, Queralt-Tomas ML, López-Pablo C, et al. Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults--Ineffectiveness of Oral Anticoagulation Treatment with VKA. Biomed Res Int. 2015;2015:134756.
Article
PubMed
PubMed Central
Google Scholar
Clua-Espuny JL, Lechuga-Duran I, Bosch-Princep R, Roso-Llorach A, Panisello-Tafalla A, Lucas-Noll J, et al. Prevalence of undiagnosed atrial fibrillation and of that not being treated with anticoagulant drugs: the AFABE study. Rev Esp Cardiol (Engl Ed). 2013;66:545–52.
Article
Google Scholar
Andersson T, Magnuson A, Bryngelsson I-L, Frøbert O, Henriksson KM, Edvardsson N, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013;34:1061–7.
Article
PubMed
PubMed Central
Google Scholar
Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422–34.
Article
PubMed
Google Scholar
Spratt N, Wang Y, Levi C, Ng K, Evans M, Fisher J. A prospective study of predictors of prolonged hospital stay and disability after stroke. J Clin Neurosci. 2003;10:665–9.
Article
PubMed
Google Scholar
Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med. 2007;39:371–91.
Article
CAS
PubMed
Google Scholar
Ruigómez A, Johansson S, Wallander MA, Rodríguez LAG. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol. 2002;55:358–63.
Article
PubMed
Google Scholar
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492–501.
Article
CAS
PubMed
Google Scholar
van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441–8.
Article
PubMed
Google Scholar
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.
Article
PubMed
Google Scholar
López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.
Article
PubMed
PubMed Central
Google Scholar
Camm AJ, Lip GYH, de Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47.
Article
PubMed
Google Scholar
Rocket AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340–347.e1.
Article
CAS
Google Scholar
Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
Article
CAS
PubMed
Google Scholar
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
Article
CAS
PubMed
Google Scholar
Brasier N, Raichle CJ, Dörr M, Becke A, Nohturfft V, Weber S, et al. Detection of atrial fibrillation with a smartphone camera: first prospective, international, two-centre, clinical validation study (DETECT AF PRO). Europace. 2019;21:41–7.
Article
PubMed
Google Scholar
Koenig N, Seeck A, Eckstein J, Mainka A, Huebner T, Voss A, et al. Validation of a New Heart Rate Measurement Algorithm for Fingertip Recording of Video Signals with Smartphones. Telemed J E Health. 2016;22:631–6.
Article
PubMed
Google Scholar
Drummond MF, Sculpher M, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford Univ. Press; 2007.
Google Scholar
Schöffski O, Claes C. Das Design einer gesundheitsökonomischen Studie. In: Schöffski O, Schulenburg J-MG, editors. Gesundheitsökonomische Evaluationen: Studienausgabe. Berlin, Heidelberg, s.l.: Springer Berlin Heidelberg; 2002. p. 51–122.
Chapter
Google Scholar
Schöffski O, Greiner W. Das QALY-Konzept zur Verknüpfung von Lebensqualitätseffekten mit ökonomischen Daten. In: Schöffski O, Schulenburg J-MG, editors. Gesundheitsökonomische Evaluationen: Studienausgabe. Berlin, Heidelberg, s.l.: Springer Berlin Heidelberg; 2002. p. 367–99.
Chapter
Google Scholar
Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg L, et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace. 2015;17:1023–9.
Article
PubMed
Google Scholar
Welton NJ, McAleenan A, Thom HH, Davies P, Hollingworth W, Higgins JP, et al. Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis: Health Technology Assessment. Health Technol Assess. 2017;21:1–236.
Article
PubMed
PubMed Central
Google Scholar
Health Information and Quality Authority. Health technology assessment (HTA) of a national screening programme for atrial fibrillation in primarycare. Dublin; 2015. http://www.hiqa.ie/sites/default/files/2017-02/HTA-of-Screening-for-Atrial-Fibrillation.pdf.
Pletscher M, Plessow R, Eichler K, Wieser S. Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. Swiss Med Wkly. 2013;143:w13732.
PubMed
Google Scholar
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.
Article
CAS
PubMed
Google Scholar
Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance. Ann Intern Med. 2005;142:323–32.
Article
PubMed
PubMed Central
Google Scholar
Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost. 2013;110:213–22.
Article
CAS
PubMed
Google Scholar
Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15:486–93.
Article
PubMed
Google Scholar
Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kermer P, Liman J, et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF RANDOMISED ): an open-label randomised controlled trial. Lancet Neurol. 2017;16:282–90.
Article
PubMed
Google Scholar
Statistisches Bundesamt. Sterbetafel (Periodensterbetafel) 2015: Deutschland, Jahre, Geschlecht, Vollendetes Alter: URL: https://www-genesis.destatis.de/genesis/online/link/tabelleErgebnis/12621-0001. 2015.
Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-Term Survival and Causes of Death After Stroke. Stroke. 2001;32:2131–6.
Article
CAS
PubMed
Google Scholar
WMT J, CJM K, Brouwers PJAM, Kappelle LJ, Vaartjes I. Time trends in incidence, case fatality, and mortality of intracerebral hemorrhage. Neurology. 2015;85:1318–24.
Article
Google Scholar
Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke. 2004;35:731–5.
Article
PubMed
Google Scholar
Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, et al. A Prospective Community-Based Study of Stroke in Germany The Erlangen Stroke Project (ESPro) Incidence and Case Fatality at 1, 3, and 12 Months. Stroke. 1998;29:2501–6.
Article
CAS
PubMed
Google Scholar
Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500–10.
Article
PubMed
Google Scholar
Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70:1486–90.
PubMed
Google Scholar
Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229–34.
Article
CAS
PubMed
Google Scholar
Krejczy M, Harenberg J, Marx S, Obermann K, Frölich L, Wehling M. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. J Thromb Thrombolysis. 2014;37:507–23.
Article
PubMed
Google Scholar
Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120:700–5.
Article
PubMed
PubMed Central
Google Scholar
Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43:736–49.
Article
PubMed
Google Scholar
Canadian Agency for Drugs and Technologies in Health. Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation. CADTH Technol Overv. 2013;3:e3202.
Google Scholar
Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24:1021–33.
Article
PubMed
Google Scholar
Sullivan PW, Ghushchyan V. Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States. Med Decis Making. 2006;26:410–20.
Article
PubMed
PubMed Central
Google Scholar
Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562–70.
Article
PubMed
Google Scholar
Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829–36.
Article
CAS
PubMed
Google Scholar
O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293:699–706.
Article
CAS
PubMed
Google Scholar
Golicki D, Niewada M, Buczek J, Karlińska A, Kobayashi A, Janssen MF, et al. Validity of EQ-5D-5L in stroke. Qual Life Res. 2015;24:845–50.
Article
PubMed
Google Scholar
Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1–11.
Article
PubMed
Google Scholar
Thomson R, Parkin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet. 2000;355:956–62.
Article
CAS
PubMed
Google Scholar
Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J. 2007;28:2346–53.
Article
PubMed
Google Scholar
Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener H-C, Dubner SJ, et al. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69:777–85.
Article
PubMed
Google Scholar
Bundesvereinigung K. Einheitlicher Bewertungsmaßstab (EBM): Stand: 1. Berlin: Quartal 2018; 2018.
Google Scholar
Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32:2735–40.
Article
CAS
PubMed
Google Scholar
Statistisches Bundesamt. Verbraucherpreise für Deutschland, 2010=100: Abteilung 06: Gesundheitspflege. 2018. https://www.destatis.de/DE/ZahlenFakten/GesamtwirtschaftUmwelt/Preise/Verbraucherpreisindizes/Tabellen_/VerbraucherpreiseKategorien.html?cms_gtp=145116_list%253D2.
Google Scholar
InEK - Institut für das Entgeltwesen im Krankenhaus. G-DRG-Browser 2016_2017. 2018. https://www.g-drg.de/Datenbrowser_und_Begleitforschung/Datenveroeffentlichung_gem._21_KHEntgG/G-DRG-Browser_2016_2017. Accessed 23 Oct 2018.
Google Scholar
Bundesversicherungsamt. Festlegung der zu berücksichtigenden Krankheiten nach § 31 Abs. 4 Satz 1 RSAV (29.02.2016). 2017.
Google Scholar